Sangamo Therapeutics (SGMO) Return on Sales (2016 - 2025)
Sangamo Therapeutics has reported Return on Sales over the past 16 years, most recently at 2.63% for Q4 2025.
- Quarterly results put Return on Sales at 2.63% for Q4 2025, up 97.0% from a year ago — trailing twelve months through Dec 2025 was 3.11% (down 138.0% YoY), and the annual figure for FY2025 was 3.11%, down 141.0%.
- Return on Sales for Q4 2025 was 2.63% at Sangamo Therapeutics, up from 60.12% in the prior quarter.
- Over the last five years, Return on Sales for SGMO hit a ceiling of 0.22% in Q3 2024 and a floor of 102.06% in Q1 2024.
- Median Return on Sales over the past 5 years was 2.08% (2022), compared with a mean of 17.35%.
- Biggest five-year swings in Return on Sales: plummeted -10219bps in 2024 and later skyrocketed 10039bps in 2025.
- Sangamo Therapeutics' Return on Sales stood at 2.16% in 2021, then rose by 11bps to 1.91% in 2022, then plummeted by -1447bps to 29.53% in 2023, then surged by 88bps to 3.6% in 2024, then increased by 27bps to 2.63% in 2025.
- The last three reported values for Return on Sales were 2.63% (Q4 2025), 60.12% (Q3 2025), and 1.09% (Q2 2025) per Business Quant data.